Impact of Fingolimod Adherence on Outcomes
NCT05141669 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 694
Last updated 2021-12-16
Summary
This study was a retrospective observational claims data study of commercial and Medicare Advantage with Part D (MAPD) patients initiating fingolimod.
Conditions
Interventions
- DRUG
-
Fingolimod
Participants who initiated fingolimod to treat multiple sclerosis (MS)
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
Novartis Pharmaceuticals · Novartis Pharmaceuticals
Eligibility
- Min Age
- 18 Years
- Max Age
- 85 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2020-05-18
- Primary Completion
- 2020-11-20
- Completion
- 2020-11-20
Countries
- United States
Study Locations
More Related Trials
-
Efficacy of Fingolimod in de Novo Patients Versus Fingolimod in Patients Previously Treated With a First Line Disease Modifying Therapy
NCT01498887 ·Status: COMPLETED ·Phase: PHASE4
-
Evaluation of Patient Retention of Fingolimod vs. Currently Approved Disease Modifying Therapy in Patients With Relapsing Remitting Multiple Sclerosis.
NCT01623596 ·Status: COMPLETED ·Phase: PHASE4
-
Safety and Tolerability of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis
NCT01497262 ·Status: COMPLETED ·Phase: PHASE3
-
Fingolimod -Response According to Coping - Evaluation
NCT01420055 ·Status: COMPLETED ·Phase: PHASE4
-
Safety and Efficacy of Fingolimod in MS Patients in China
NCT01941004 ·Status: WITHDRAWN ·Phase: PHASE3
-
Difference in Efficacy of Natalizumab Versus Fingolimod for the Treatment of Multiple Sclerosis
NCT01981161 ·Status: COMPLETED
-
Long-term Safety and Tolerability of 0.5 mg Fingolimod in Patients With Relapsing Forms of Multiple Sclerosis
NCT01201356 ·Status: COMPLETED ·Phase: PHASE3
-
Effect of Fingolimod on Neurodegeneration
NCT02575365 ·Status: TERMINATED ·Phase: PHASE4
-
Efficacy and Safety of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis
NCT00289978 ·Status: COMPLETED ·Phase: PHASE3
-
Fingolimod Versus Dimethyl-fumarate in Multiple Sclerosis
NCT03345940 ·Status: TERMINATED ·Phase: PHASE4
-
Disease Control and Safety in Patients With Relapsing Remitting Multiple Sclerosis (RRMS) Switching From Natalizumab to Fingolimod
NCT01499667 ·Status: TERMINATED ·Phase: PHASE3
-
Effect of an Individualized Patient Support Program on Treatment Satisfaction in Fingolimod-treated Patients With RRMS
NCT01709812 ·Status: WITHDRAWN ·Phase: PHASE4
-
Long-term Efficacy and Safety of Fingolimod (FTY720) in Patients With Relapsing-remitting Multiple Sclerosis
NCT00662649 ·Status: COMPLETED ·Phase: PHASE3
-
A 6-month, Randomized, Open-label, Patient OutComes, Safety and Tolerability Study of Fingolimod (FTY720) 0.5 mg/Day vs. Comparator in Patients With Relapsing Forms of Multiple Sclerosis
NCT01216072 ·Status: COMPLETED ·Phase: PHASE4
-
Fingolimod Versus Interferon Beta 1b in Cognitive Symptoms
NCT01333501 ·Status: COMPLETED ·Phase: PHASE4
-
Effects of Gilenya (Fingolimod) on Thalamus Pathology and Cognitive Impairment in Patients With Relapsing Forms of Multiple Sclerosis
NCT02021162 ·Status: COMPLETED
-
Efficacy and Safety of Fingolimod (FTY720) in Patients With Relapsing-remitting Multiple Sclerosis
NCT00355134 ·Status: COMPLETED ·Phase: PHASE3
-
MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone
NCT01633112 ·Status: TERMINATED ·Phase: PHASE3
-
A Study of Immune Phenotype Biomarkers in Patients With Relapsing Multiple Sclerosis (RMS) After Treatment With 0.5mg Fingolimod
NCT03257358 ·Status: COMPLETED ·Phase: PHASE4
-
Safety and Efficacy Study of Fingolimod in Taiwanese Adults (≥ 20years) With Relapsing Remitting Multiple Sclerosis
NCT04480853 ·Status: RECRUITING ·Phase: PHASE4
-
Effect of Treatment With Fingolimod on the Immune Response Following Seasonal Flu Vaccination and Tetanus Booster Injection in Patients With Relapsing Multiple Sclerosis (MS)
NCT01199861 ·Status: COMPLETED ·Phase: PHASE3
-
Administration of Fingolimod in Greek Patients With Multiple Sclerosis.
NCT06949956 ·Status: NOT_YET_RECRUITING
-
Evaluation of Patient Reported Outcomes in RRMS Patients Candidates for MS Therapy Change and Transitioned to Fingolimod 0.5 mg (EPOC)
NCT01534182 ·Status: COMPLETED ·Phase: PHASE4
-
PROFILE - Evaluation of QoL and PRO Outcomes in Patients Taking Fingolimod
NCT02335892 ·Status: COMPLETED
-
Long-term, Open-label, Multicenter Study Assessing Long-term Cardiovascular Risks
NCT02232061 ·Status: COMPLETED ·Phase: PHASE4